Mochida Pharmaceutical strives to provide medicines that correspond to patients ongoing requirements as quickly as we can.
We maximize foresight and originality in all processes, based on our unique research and development capabilities and diverse technological know-how cultivated over many years.
In order to make our pharmaceutical research even more efficient, we are enhancing development pipelines by introducing candidate drugs for development at an early stage by promoting “open innovation.”
Open Innovation Drug Discovery
At Mochida, we are engaging in proactive open innovation research to make drug discovery research more efficient, promoting collaborative drug discovery research and applied research of new core technologies with the academia for the purpose of developing pharmaceuticals.
|MND-2119||ethyl icosapentate||Filed||Hyperlipidemia||Oral||In-house development<Japan>|
|MD-0901||mesalazine||Phase Ⅲ||Ulcerative colitis
|Oral||Licensed-in from Shire Pharmaceuticals Group (now part of Takeda)
|Oral||Licensed-in from Lundbeck
|MD-120||desvenlafaxine||Phase Ⅲ||Depression||Oral||Co-development with Pfizer<Japan>|
|MND-21||ethyl icosapentate||Phase Ⅲ||Hypertriglyceridemia||Oral||Collaboration with Sumitomo Pharmaceuticals (Suzhou)<China>|
|ACT-541468||daridorexant||Phase Ⅲ||Insomnia||Oral||Co-development with Idorsia Pharmaceuticals Japan<Japan>|
|MD-711||treprostinil||Phase Ⅱ / Ⅲ||Pulmonary arterial hypertension||Inhalant||Licensed-in from United Therapeutics
|MD-711||treprostinil||Phase Ⅱ / Ⅲ||Pulmonary hypertension associated with interstitial lung disease||Inhalant||Licensed-in from United Therapeutics
|dMD-001||sodium alginate||Therapeutic confirmatory study||Articular cartilage lesion||In-house development<Japan>|